Anaplastic medulloblastoma in a child with Duchenne muscular dystrophy

2012 ◽  
Vol 10 (1) ◽  
pp. 21-24 ◽  
Author(s):  
Machiel van den Akker ◽  
Paul Northcott ◽  
Michael D. Taylor ◽  
William Halliday ◽  
Ute Bartels ◽  
...  

A 9-year-old boy with known Duchenne type muscular dystrophy (DMD) presented with signs of increased intracranial pressure. Radiological investigations revealed a lesion in the midline of the posterior fossa. Subtotal resection was performed. Pathology findings were consistent with the diagnosis of anaplastic medulloblastoma. The postoperative lumbar CSF was positive for malignant cells. Postoperatively, the patient showed severe neurological deterioration and lost his capacity to walk. He was treated with craniospinal radiation followed by nonintensive chemotherapy. At 30 months postsurgery, he was still in complete remission but had not recovered his walking ability. This is the second report of a malignant brain tumor in a boy with DMD. The possible link between the 2 conditions is discussed, as are ethical considerations regarding the management of medulloblastoma in children with DMD.

2019 ◽  
Vol 29 ◽  
pp. S108
Author(s):  
N. Goemans ◽  
J. Signorovitch ◽  
G. Sajeev ◽  
M. Fillbrunn ◽  
H. Wong ◽  
...  

2019 ◽  
Vol 22 ◽  
pp. S864
Author(s):  
N. Goemans ◽  
J. Signorovitch ◽  
G. Sajeev ◽  
M. Fillbrunn ◽  
H. Wong ◽  
...  

2012 ◽  
Vol 70 (3) ◽  
pp. 191-195 ◽  
Author(s):  
Elaine C. da Silva ◽  
Darlene L. Machado ◽  
Maria B. D. Resende ◽  
Renata F. Silva ◽  
Edmar Zanoteli ◽  
...  

OBJECTIVE: To assess the evolution of motor function in patients with Duchenne muscular dystrophy (DMD) treated with steroids (prednisolone or deflazacort) through the Motor Function Measure (MFM), which evaluates three dimensions of motor performance (D1, D2, D3). METHODS: Thirty-three patients with DMD (22 ambulant, 6 non-ambulant and 5 who lost the capacity to walk during the period of the study) were assessed using the MFM scale six times over a period of 18 months. RESULTS: All the motor functions remained stable for 14 months in all patients, except D1 for those who lost their walking ability. In ambulant patients, D2 (axial and proximal motor capacities) motor functions improved during six months; an improvement in D3 (distal motor capacity) was noted during the total follow-up. D1 (standing posture and transfers) and total score were useful to predict the loss of the ability to walk. CONCLUSIONS: The use of the MFM in DMD patients confirms the benefits of the steroid treatment for slowing the progression of the disease.


2012 ◽  
Vol 43 (02) ◽  
Author(s):  
E Sarrazin ◽  
M von der Hagen ◽  
U Schara ◽  
K von Au ◽  
A Kaindl

Sign in / Sign up

Export Citation Format

Share Document